Brief: Lipigon Receives CTA Approval For Lipid-Lowering Candidate Lipisense

Lipigon Pharmaceuticals AB

28/04/2022 08:38

April 28 (Reuters) - Lipigon Pharmaceuticals AB  LPGO.ST :
    * SAID ON WEDNESDAY RECEIVED APPROVAL FROM SWEDISH MEDICAL
PRODUCTS AGENCY TO START CLINICAL PHASE I STUDY WITH
LIPID-LOWERING DRUG CANDIDATE LIPISENSE
    * TRIAL AIMS TO DOCUMENT SAFETY PROFILE OF LIPISENSE AND
PHARMACOKINETIC PROPERTIES AS WELL AS PHARMACODYNAMIC EFFECTS
VIA BIOMARKERS

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nBQN8s8S1s
 Further company coverage:  LPGO.ST  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))